Detalhe da pesquisa
1.
Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms.
Blood
; 115(15): 3109-17, 2010 Apr 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-20130243
2.
Janus kinase inhibitor INCB20 has antiproliferative and apoptotic effects on human myeloma cells in vitro and in vivo.
Mol Cancer Ther
; 8(1): 26-35, 2009 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-19139110
3.
Selective inhibition of ADAM metalloproteases as a novel approach for modulating ErbB pathways in cancer.
Clin Cancer Res
; 13(6): 1892-902, 2007 Mar 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-17363546
4.
Discovery of a potent, selective, and orally active human epidermal growth factor receptor-2 sheddase inhibitor for the treatment of cancer.
J Med Chem
; 50(4): 603-6, 2007 Feb 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-17256836
5.
Selective inhibition of ADAM metalloproteases blocks HER-2 extracellular domain (ECD) cleavage and potentiates the anti-tumor effects of trastuzumab.
Cancer Biol Ther
; 5(6): 648-56, 2006 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-16627988
6.
INCB16562, a JAK1/2 selective inhibitor, is efficacious against multiple myeloma cells and reverses the protective effects of cytokine and stromal cell support.
Neoplasia
; 12(1): 28-38, 2010 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-20072651
7.
Combined inhibition of Janus kinase 1/2 for the treatment of JAK2V617F-driven neoplasms: selective effects on mutant cells and improvements in measures of disease severity.
Clin Cancer Res
; 15(22): 6891-900, 2009 Nov 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-19887489
8.
Synergistic inhibition with a dual epidermal growth factor receptor/HER-2/neu tyrosine kinase inhibitor and a disintegrin and metalloprotease inhibitor.
Cancer Res
; 68(17): 7083-9, 2008 Sep 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-18757423